NCT01334671 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Albrecht C, Kaeppel N, Gauglitz G
Two immunoassay formats for fully automated CRP detection in human serum. Anal Bioanal Chem. 2008 Jul;391(5):1845-52. doi: 10.1007/s00216-008-2093-x. Epub 2008 May 3.
Antoniades C, Tousoulis D, Vasiliadou C, Pitsavos C, Chrysochoou C, Panagiotakos D, Tentolouris C, Marinou K, Koumallos N, Stefanadis C
Genetic polymorphism on endothelial nitric oxide synthase affects endothelial activation and inflammatory response dur
Katayama T, Nakashima H, Yonekura T, Honda Y, Suzuki S, Yano K
[Significance of acute-phase inflammatory reactants as an indicator of prognosis after acute myocardial infarction: which is the most useful predictor?]. J Cardiol. 2003 Aug;42(2):49-56. Japa
Topol EJ
Intensive statin therapy--a sea change in cardiovascular prevention. N Engl J Med. 2004 Apr 8;350(15):1562-4. Epub 2004 Mar 8.
Walter DH, Dimmeler S, Zeiher AM
Effects of statins on endothelium and endothelial progenitor cell recruitment. Semin Vasc Med. 2004 Nov;4(4):385-93. Review.
Wilson AM, Ryan MC, Boyle AJ
The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol. 2006 Jan 26;106(3):291-7. Review.
Wu TL, I Chen Tsai, Chang PY, Tsao KC, Sun CF, Wu LL, Wu JT
Establishment of an in-house ELISA and the reference range for serum amyloid A (SAA): complementarity between SAA and C-reactive protein as markers of inflammation. Clin Chim Acta. 2007 Feb;376(

The Clinical Effect of Intensive Statin Therapy in STEMI(ST-elevated Myocardial Infarction) Patients Before Emergency PCI(Percutaneous Coronary Intervention)

Details for clinical trial NCT01334671

Clinical trial NCT01334671 - References